FDA has accepted and granted priority review to the supplemental New Drug Application for Xalkori for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive.
Last week’s issue of The Cancer Letter included an obituary that the entire staff at The Cancer Letter had been dreading for years: Abdallah Abou Zahr, an oncologist at Roger Maris Cancer Center in Fargo, ND, died Jan. 23 of a liposarcoma after a five-year battle with the disease.
